---
title: "Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases | GILD Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280221004.md"
description: "Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases | GILD Stock News"
datetime: "2026-03-23T14:15:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280221004.md)
  - [en](https://longbridge.com/en/news/280221004.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280221004.md)
---

# Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases | GILD Stock News

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases | GILD Stock News

### Related Stocks

- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/286893590.md)
- [Gilead teams up with WHO again to eliminate parasitic tropical disease](https://longbridge.com/en/news/287256930.md)
- [‘Solve all diseases,’ you say?](https://longbridge.com/en/news/287121830.md)
- [Medtronic plans to buy SPR Therapeutics for $650 million to expand pain treatment options](https://longbridge.com/en/news/287081570.md)
- [New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology | GILD Stock News](https://longbridge.com/en/news/287272453.md)